Clinical Practice Guideline for Headache Disorders 2021
Abstract
The International Headache Society published the International Classification of Headache Disorders, 3rd edition in 2018. In this classification, Chapter 3—previously “Cluster headache and other trigeminal‐autonomic cephalalgias”—was renamed “Trigeminal‐autonomic cephalalgias (TACs).” Trigeminal‐autonomic cephalalgias are a group of disorders characterized by unilateral severe headache and cranial autonomic symptoms, with cluster headache as a representative condition. Several major revisions have also been made regarding the diagnostic criteria for trigeminal‐autonomic cephalalgias in terms of ictal symptomatology and the duration of remission period. Moreover, calcitonin gene‐related peptide‐targeting treatments have enabled significant improvements in migraine management to be made. In Japan, in response to these advances in headache medicine, the Clinical Practice Guideline for Headache Disorders was revised by the Study Group for Headache Clinical Practice Guideline Development. The new guidelines include the latest information and present global standards of management for both primary and secondary headache disorders in consideration of local labelling and regulatory approvals. The guideline comprises eight chapters: “I. Headache: general considerations,” “II. Migraine,” “III. Tension‐type headache,” “IV. Trigeminal‐autonomic cephalalgias,” “V. Other primary headache disorders,” “VI. Medication‐overuse headache (MOH),” “VII. Headaches in children,” and “VIII.…
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.